Story perspectives

Critics Slam U.S. Vaccine Trial; Ethics in Question

1/21/2026

47 5

Summary

Story summary

The U.S. Department of Health and Human Services faces criticism over a Guinea-Bissau vaccine study funding a trial of 14,000 infants, with half receiving hepatitis B vaccine.
Critics liken it to the unethical Tuskegee study.
Africa CDC, the African Union health agency, reportedly halted the trial, raising ethical concerns about vulnerable populations.
An HHS spokesperson dismissed Africa CDC as a "fake organization" and called its statements unreliable.

1 of 1

Story summary

The U.S. Department of Health and Human Services faces criticism over a Guinea-Bissau vaccine study funding a trial of 14,000 infants, with half receiving hepatitis B vaccine.
Critics liken it to the unethical Tuskegee study.
Africa CDC, the African Union health agency, reportedly halted the trial, raising ethical concerns about vulnerable populations.
An HHS spokesperson dismissed Africa CDC as a "fake organization" and called its statements unreliable.